Clinical Trials Logo

Metastatic Soft Tissue Sarcoma clinical trials

View clinical trials related to Metastatic Soft Tissue Sarcoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04551430 Active, not recruiting - Clinical trials for Metastatic Soft-tissue Sarcoma

Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Start date: January 5, 2021
Phase: Phase 2
Study type: Interventional

The hypothesis of this study is that the response rate of soft tissue sarcoma will be improved with the addition of PD-1 and CTLA-4 inhibition to cabozantinib, and that cabozantinib priming will increase the response to nivolumab and ipilimumab.

NCT ID: NCT04200443 Active, not recruiting - Clinical trials for Metastatic Soft Tissue Sarcoma

Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma

Start date: January 14, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well cabozantinib and temozolomide work in treating patients with leiomyosarcoma or other soft tissue sarcoma that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving cabozantinib and temozolomide may work better than either one alone in treating patients with leiomyosarcoma or other soft tissue sarcoma. Cabozantinib is an investigational drug, which means that it has not been approved by the United States (US) Food and Drug Administration (FDA) or any other regulatory agencies for sale or use by the public for the indication under investigation in this study.

NCT ID: NCT03793361 Active, not recruiting - Clinical trials for Metastatic Soft Tissue Sarcoma

Phase II Study of Regorafenib as Maintenance Therapy

Start date: May 15, 2019
Phase: Phase 2
Study type: Interventional

Multicenter double-blind placebo-controlled randomized Phase II study comparing regorafenib® to placebo, as maintenance therapy in metastatic soft-tissue non-adipocytic sarcomas experiencing stable disease or response after 6 cycles of doxorubicin-based chemotherapy as 1st line chemotherapy.

NCT ID: NCT03660930 Active, not recruiting - Clinical trials for Metastatic Soft Tissue Sarcoma

Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

Start date: April 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of nab-sirolimus and how well it works when given together with pazopanib hydrochloride in treating participants with nonadipocytic soft tissue sarcomas that has spread to other places in the body (advanced). Nab-sirolimus and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.